• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    4/18/23 1:31:32 PM ET
    $ALLR
    $BLCM
    $BXRX
    $CFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALLR alert in real time by email

    Gainers

    • Dermata Therapeutics (NASDAQ:DRMA) shares increased by 73.4% to $2.74 during Tuesday's regular session. As of 13:30 EST, Dermata Therapeutics's stock is trading at a volume of 64.5 million, which is 5704.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.3 million.
    • Allarity Therapeutics (NASDAQ:ALLR) stock moved upwards by 36.43% to $1.61. Trading volume for Allarity Therapeutics's stock is 62.3 million as of 13:30 EST. This is 10920.1% of its average full-day volume over the last 100 days. The company's market cap stands at $1.5 million.
    • SAB Biotherapeutics (NASDAQ:SABS) shares increased by 29.83% to $1.0. Trading volume for this security as of 13:30 EST is 34.8 million, which is 6943.8% of its average full-day volume over the last 100 days. The company's market cap stands at $50.3 million. As per the news, the Q4 earnings report came out 2 days ago.
    • Baudax Bio (NASDAQ:BXRX) stock moved upwards by 27.01% to $2.29. The current volume of 1.3 million shares is 109.4% of Baudax Bio's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $5.9 million.
    • SenesTech (NASDAQ:SNES) shares increased by 21.25% to $1.54. Trading volume for this security as of 13:30 EST is 427.8K, which is 141.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.5 million.
    • Trevi Therapeutics (NASDAQ:TRVI) stock increased by 19.46% to $2.21. Trevi Therapeutics's stock is trading at a volume of 365.2K shares as of 13:30 EST. This is 780.8% of its average full-day volume over the last 100 days. The company's market cap stands at $132.7 million.

    Losers

    • Tempest Therapeutics (NASDAQ:TPST) shares declined by 37.3% to $2.32 during Tuesday's regular session. Tempest Therapeutics's stock is trading at a volume of 136.3K shares as of 13:30 EST. This is 525.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $24.5 million.
    • Relay Therapeutics (NASDAQ:RLAY) shares declined by 32.17% to $12.36. Trading volume for this security as of 13:30 EST is 8.0 million, which is 691.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.5 billion.
    • Pear Therapeutics (NASDAQ:PEAR) shares decreased by 31.39% to $0.03. Pear Therapeutics's stock is trading at a volume of 38.9 million shares as of 13:30 EST. This is 493.6% of its average full-day volume over the last 100 days. The company's market cap stands at $4.6 million.
    • Bellicum Pharmaceuticals (NASDAQ:BLCM) stock fell 29.83% to $0.4. Trading volume for Bellicum Pharmaceuticals's stock is 2.7 million as of 13:30 EST. This is 304.8% of its average full-day volume over the last 100 days. The company's market cap stands at $3.6 million.
    • ContraFect (NASDAQ:CFRX) stock declined by 26.21% to $1.69. As of 13:30 EST, this security is trading at a volume of 3.7 million shares, making up 139.8% of its average full-day volume over the last 100 days. The company's market cap stands at $2.6 million.
    • Kiromic BioPharma (NASDAQ:KRBP) stock decreased by 24.8% to $3.61. The current volume of 185.4K shares is 109.2% of Kiromic BioPharma's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $2.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLR
    $BLCM
    $BXRX
    $CFRX

    CompanyDatePrice TargetRatingAnalyst
    Relay Therapeutics Inc.
    $RLAY
    1/26/2026$14.00Perform → Outperform
    Oppenheimer
    Tempest Therapeutics Inc.
    $TPST
    1/22/2026$11.00Neutral → Buy
    H.C. Wainwright
    SAB Biotherapeutics Inc.
    $SABS
    12/19/2025$15.00Buy
    Guggenheim
    Relay Therapeutics Inc.
    $RLAY
    12/12/2025$13.00Equal Weight → Overweight
    Wells Fargo
    Trevi Therapeutics Inc.
    $TRVI
    11/13/2025$13.00Outperform
    Leerink Partners
    SAB Biotherapeutics Inc.
    $SABS
    9/17/2025$7.00Outperform
    Leerink Partners
    Relay Therapeutics Inc.
    $RLAY
    9/4/2025$15.00Buy
    Guggenheim
    Trevi Therapeutics Inc.
    $TRVI
    8/21/2025$18.00Overweight
    Morgan Stanley
    More analyst ratings

    $ALLR
    $BLCM
    $BXRX
    $CFRX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by SAB Biotherapeutics Inc.

    SCHEDULE 13D/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)

    3/23/26 4:25:55 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tempest Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

    8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

    3/23/26 8:17:19 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Relay Therapeutics Inc.

    SCHEDULE 13G - Relay Therapeutics, Inc. (0001812364) (Subject)

    3/19/26 4:07:15 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $BLCM
    $BXRX
    $CFRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    3/17/26 8:10:19 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SVP, Regulatory Affairs Bedoya-Toro Munera Maria E bought $1,270 worth of shares (1,000 units at $1.27), increasing direct ownership by 8,333% to 1,012 units (SEC Form 4)

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    3/17/26 5:44:21 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $ALLR
    $BLCM
    $BXRX
    $CFRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempest Therapeutics Announces Up To $6 Million Private Placement

    BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) (the "Company"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 925,927 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 925,927 shares of common stock and short-term series B warrants to purchase up to 925,927 shares of common stock, at a combined purchase price of $2.16 per share of common stock (or $2.159 per pre-funded warrant in lieu thereof) and accompanyi

    3/23/26 8:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

    MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the closing of an underwritten public offering of 19,324,677 shares of its common stock at a public offering price of $3.85 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 2,753,246 shares of common stock at a public offering price of $3.8499 per pre-funded warrant, which represents the per share public offering price less the $0.0001 per share exercise price for each pre-funded war

    3/19/26 4:01:00 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

    MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the pricing of an underwritten public offering of 19,324,677 shares of its common stock at a public offering price of $3.85 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 2,753,246 shares of common stock at a public offering price of $3.8499 per pre-funded warrant, which represents the per share public offering price less the $0.0001 per share exercise price for each pre-funded war

    3/17/26 10:46:23 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $BLCM
    $BXRX
    $CFRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    3/17/26 8:10:19 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SVP, Regulatory Affairs Bedoya-Toro Munera Maria E bought $1,270 worth of shares (1,000 units at $1.27), increasing direct ownership by 8,333% to 1,012 units (SEC Form 4)

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    3/17/26 5:44:21 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Relay Therapeutics Inc.

    4 - Relay Therapeutics, Inc. (0001812364) (Issuer)

    3/11/26 4:30:35 PM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $BLCM
    $BXRX
    $CFRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Relay Therapeutics upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Relay Therapeutics from Perform to Outperform and set a new price target of $14.00

    1/26/26 8:32:07 AM ET
    $RLAY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tempest Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Tempest Therapeutics from Neutral to Buy and set a new price target of $11.00

    1/22/26 8:24:05 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on SAB BIO with a new price target

    Guggenheim initiated coverage of SAB BIO with a rating of Buy and set a new price target of $15.00

    12/19/25 8:51:08 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $BLCM
    $BXRX
    $CFRX
    Leadership Updates

    Live Leadership Updates

    View All

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

    David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D. to its Board of Directors as Chair of the Board and the appointment of Rita Jain, M.D., as an independent director, both effective immediately. "We are excited to welcome Dr. David Zaccardelli and Dr. Rita Jain to our Board of Directors. I, along with the rest of our Board, am confi

    1/7/26 8:00:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer

    Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that David Hastings will assume the role of Chief Financial Officer effective January 6, 2026.  www.trevitherapeutics.com (PRNewsfoto/Trevi

    12/4/25 7:30:00 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BLCM
    $BXRX
    $CFRX
    Financials

    Live finance-specific insights

    View All

    Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates

    Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track to initiate a Phase 2b clinical trial for the treatment of patients with refractory chronic cough in the second quarter of 2026 Company ended 2025 with $188.3 million in cash, cash equivalents and marketable securities, with expected cash runway into 2028 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., March 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investig

    3/17/26 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech Announces 2025 Financial Results Driven by Strong Growth in E-Commerce

    SURPRISE, Ariz., March 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, today announced financial results for the fourth quarter and the full year ended December 31, 2025. 2025 HighlightsRevenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company's overall e-commerce channels despite the impact associated with the Company's transition to directly managing Amazon sales of Evolve® Rat and Evolve Mouse. Excluding this transition-related impact, we estimate re

    3/12/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026

    NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, March 17, 2026, at 4:30 p.m. ET, to provide business updates and review the Company's financial results for the fourth quarter and year ended December 31, 2025.  Conference Call and WebcastTo register for the live co

    3/10/26 4:05:00 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $BLCM
    $BXRX
    $CFRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:12:23 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

    SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

    11/14/24 5:51:58 PM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care